immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.
Company profile
Ticker
IBRX
Exchange
Website
CEO
Patrick Soon-Shiong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Conkwest, Inc., NantKwest, Inc., ZelleRx Corp
SEC CIK
Corporate docs
Subsidiaries
Infacell Therapeutics, Inc. • Inex Bio, Inc. • NantCell, Inc. • Etubics Corporation • Altor BioScience, LLC • Altor BioScience Manufacturing Company, LLC • Receptome, Inc. • VBC Holdings LLC • GlobeImmune, Inc. • Immunotherapy NANTibody, LLC ...
IBRX stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
EFFECT
Notice of effectiveness
3 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
8-K
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
23 Apr 24
S-3ASR
Automatic shelf registration
17 Apr 24
S-3
Shelf registration
28 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 133.04 mm | 133.04 mm | 133.04 mm | 133.04 mm | 133.04 mm | 133.04 mm |
Cash burn (monthly) | 44.14 mm | (no burn) | 44.71 mm | 50.12 mm | 35.66 mm | 32.45 mm |
Cash used (since last report) | 92.57 mm | n/a | 93.77 mm | 105.12 mm | 74.79 mm | 68.06 mm |
Cash remaining | 40.46 mm | n/a | 39.26 mm | 27.92 mm | 58.24 mm | 64.97 mm |
Runway (months of cash) | 0.9 | n/a | 0.9 | 0.6 | 1.6 | 2.0 |
Institutional ownership, Q1 2024
42.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 70 |
Opened positions | 21 |
Closed positions | 63 |
Increased positions | 17 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 20.42 bn |
Total shares | 295.64 mm |
Total puts | 510.90 k |
Total calls | 1.12 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Cambridge Equities | 291.69 mm | $1.46 bn |
Sheets Smith Wealth Management | 945.72 k | $5.08 bn |
Allen Holding | 687.57 k | $3.69 bn |
BK Bank Of New York Mellon | 450.79 k | $2.42 bn |
Swiss National Bank | 263.10 k | $1.41 bn |
DekaBank Deutsche Girozentrale | 205.09 k | $1.12 mm |
Profund Advisors | 201.34 k | $1.08 bn |
China Universal Asset Management | 128.32 k | $689.00 k |
Susquehanna International | 111.39 k | $598.15 mm |
PFG Principal Financial Group Inc - Registered Shares | 73.47 k | $394.51 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | Simon Barry J. | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 159,146 | 833.93 k | 159,146 |
22 Feb 24 | Simon Barry J. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,731 | 0.00 | 45,731 |
22 Feb 24 | Regan J Lauer | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 42,439 | 222.38 k | 42,439 |
22 Feb 24 | Regan J Lauer | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,195 | 0.00 | 12,195 |
22 Feb 24 | David C. Sachs | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 424,390 | 2.22 mm | 424,390 |
22 Feb 24 | David C. Sachs | RSU Common Stock | Grant | Acquire A | No | No | 0 | 121,951 | 0.00 | 121,951 |
22 Feb 24 | Richard Adcock | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 1,591,463 | 8.34 mm | 1,591,463 |
22 Feb 24 | Richard Adcock | RSU Common Stock | Grant | Acquire A | No | No | 0 | 457,317 | 0.00 | 457,317 |
22 Feb 24 | Soon-shiong Patrick | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 1,193,597 | 6.25 mm | 1,193,597 |
22 Feb 24 | Soon-shiong Patrick | RSU Common Stock | Grant | Acquire A | No | No | 0 | 342,987 | 0.00 | 342,987 |
News
How Is The Market Feeling About ImmunityBio?
17 May 24
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
7 May 24
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
7 May 24
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
3 May 24
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
3 May 24
Press releases
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
17 May 24
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
15 May 24
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
7 May 24
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
2 May 24
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
1 May 24